The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of Cyclooxygenase 2

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Peulen, Olivier ^a   Gonzalez, Arnaud ^a   Peixoto, Paul ^a   Turtoi, Andrei ^a   Mottet, Denis ^a   Delvenne, Philippe ^a   Castronovo, Vincent ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VORINOSTAT; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; HISTONE DEACETYLASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL GROWTH; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MONOTHERAPY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHORIOALLANTOIC MEMBRANE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HUMANS; PANCREATIC NEOPLASMS; TUMOR BURDEN;

EID: 84895893042     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075102     Document Type: Article

References (63)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300 doi:10.3322/caac.20073
2. Anonymous (2011) Pancreatic cancer in the UK. Lancet 378: 1050 doi: 10.1016/S0140-6736(11)61465-7
3. Tinari N, de Tursi M, Grassadonia A, Zilli M, Stuppia L, et al. (2012) An epigenetic approach to pancreatic cancer treatment: The prospective role of histone deacetylase inhibitors. Curr Cancer Drug Targets 12: 439-452. doi: 10.2174/156800912800190884
4. Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, et al. (2008) HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 28: 243-256 doi:10.1038/onc.2008.371
5. Mottet D, Bellahcène A, Pirotte S, Waltregny D, Deroanne C, et al. (2007) Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res 101: 1237-1246 doi:10.1161/CIRCRESAHA.107.149377
6. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, et al. (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-136 doi:10.1038/sj.one. 1205108
7. Fritsche P, Seidler B, Schüler S, Schnieke A, Göttlicher M, et al. (2009) HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 58: 1399-1409 doi:10.1136/gut.2009.180711
8. Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, et al. (2009) High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 9: 395 doi:10.1186/1471-2407-9-395
9. Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, et al. (2008) Expression of hypoxia-inducible factor-1 alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36: e1-e9 doi: 10.1097/M PA. 0b013e31815f 2c2a
10. Oualssi M, Sielezneff I, Silvestre R, Sastre B, Bernard JP, et al. (2008) High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 15: 2318-2328 doi:10.1245/s10434-008-9940-z
11. Khan O, La Thangue NB (2012) HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94. doi: 10.1038/icb.2011.100
12. Kim H-J, Bae S-C (2011) Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transi Res 3: 166-179
13. ZafarSF, Nagaraju GP, El-Rayes B (2012) Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. Expert Opin Ther Targets 16: 707-718 doi: 10.1517/14728222.2012.691473
14. de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 14: 6663-6673 doi: 10.1158/1078-0432. CCR-08-0376
15. Gore L, Rothenberg ML, O'Bryant CL, Schultz MK, Sandler AB, et al. (2008) A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 14: 4517-1525 doi:10.1158/1078-0432.CCR-07-1461
16. Ellis L, Pili R (2010) Histone deacetylase inhibitors: Advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals 3: 2441-2469 doi:10.3390/ph3082441
17. Bots M, Johnstone RW (2009) Rational combinations using HDAC inhibitors. Clin Cancer Res 15: 3970-3977 doi: 10.1158/1078-0432.CCR-08-2786
18. Chun SG, Zhou W, Yee NS (2009) Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol Ther 8: 19-30. doi: 10.4161/cbt.8.14.8633
19. Iwahashi S, Ishibashi H, Utsunomiya T, Morine Y, OchirTL, et al. (2011) Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. J Med Invest 58: 106-109 doi:10.2152/jmi.58.106
20. Bai J, Demirjian A, Sui J, Marasco W, Callery MP (2006) Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 348: 1245-1253 doi:10.1016/j.bbrc.2006.07.185
21. Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, et al. (2006) Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 448: 797-804 doi:10.1007/s00428-006-0173-x.
22. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, et al. (2007) Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 1773: 1095-1106 doi:10.1016/j.bbamcr.2007.05.002
23. Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, et al. (2006) Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 17: 1096-1102 doi:10.1093/annonc/mdl081
24. Pili R, Salumbides B, Zhao M, Altiok S, Qian D, et al. (2012) Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 106: 77-84 doi:10.1038/bjc.2011.527
25. Wu S, Li RW, Li W, Li CJ (2012) Transcriptome characterization by RNA-seq unravels the mechanisms of butyrate-induced epigenomic regulation in bovine cells. PLoS ONE 7: e36940 doi:10.1371/journal.pone.0036940
26. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, et al. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163
27. Wang X, Li G, Wang A, Zhang Z, Merchan JR, et al. (2013) Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. Mol Carcinog 52: 218-228 doi:10.1002/mc.21846
28. Sun WH, Chen G-S, Ou XL, Yang Y, Luo C, et al. (2009) Inhibition of COX-2 and activation of peroxisome proliterator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett 275: 247-255 doi: 10.1016/j. canlet. 2008.10.023
29. Colby JKL, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, et al. (2008) Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 10: 782-796
30. Mukherjee P, Basu GD, Tinder TL, Subramani DB, Bradley JM, et al. (2009) Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 182: 216-224. doi: 10.4049/jimmunol.182.1.216
31. Hill R, Li Y, Tran LM, Dry S, Calvopina JH, et al. (2012) Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther 11: 2127-2137 doi: 10.1158/1535-7163. MCT-12-0342
32. Dumartin L, QuemenerC, Laklai H, Herbert J, Bicknell R, et al. (2010) Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology 137: 1595-1606 doi:10.1053/j.gastro.2009.12.061
33. Peixoto P, Castronovo V, Matheus N, Polese C, Peulen OJ, et al. (2012) HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells. Cell Death Differ 19: 1239-1252 doi:10.1038/cdd.2012.3
34. Lamour V, Le Mercier M, Lefranc F, Hagedorn M, Javerzat S, et al. (2010) Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer 126: 1797-1805 doi: 10.1002/ijc.24751
35. Deryugina El, Quigley JP (2008) Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol 130: 1119-1130 doi: 10.1007/s00418-008-0536-2
36. Tan MH, Nowak NJ, Rueyming L (1986) Characterization of a new primary human pancreatic tumor line. Cancer Invest 4: 15-23. doi: 10.3109/07357908609039823
37. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G (1975) Establishment of a continuous tumor-cell line (PANC-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15: 741-747 doi:10.1002/ijc.2910150505
38. Schoumacher RA, Ram J, lannuzzi MC, Bradbury NA, Wallace RW, et al. (1990) A cystic fibrosis pancreatic adenocarcinoma cell line. Proc Natl Acad Sci U S A 87: 4012-016. doi: 10.1073/pnas.87.10.4012
39. Detry C, Lamour V, Castronovo V, Bellahcène A (2008) CREB-1 and AP-1 transcription factors JunD and Fra-2 regulate bone sialoprotein gene expression in human breast cancer cells. Bone 42: 422-431 doi:10.1016/j.bone.2007.10.016
40. Ouaïssi M, Cabrai S, Tavares J, da Silva AC, Mathieu Daude F, et al. (2008) Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. Cancer Biol Ther 7: 523-531. doi: 10.4161/cbt.7.4.5480
41. Mehdi O, Françoise S, Sofia CL, Urs G, Kevin Z, et al. (2012) HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Pancreatology 12: 146-155 doi: 10.1016/j. pan. 2012.02.013
42. Chen LF, Fischle W, Verdin E, Greene WC (2001) Duration of nuclear NF-KB action regulated by reversible acetylation. Science 293: 1653-1657 doi: 10.1126/science. 1062374
43. Ashburner BP, Westerheide SD, Baldwin AS (2001) The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 21: 7065-7077 doi: 10.1128/MCB.21.20.7065-7077.2001
44. Broude EV, Swift ME, Vivo C, Chang BD, Davis BM, et al. (2007) p21Waf1/Cip1/Sdi1 mediates retinoblastoma protein degradation. Oncogene 26: 6954-6958 doi:10.1038/sj.one.1210516
45. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, et al. (2010) Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39: 425-435 doi: 10.1097/M PA. 0b013e3181 d 5963
46. Turtoi A, Musmeci D, Wang Y, Dumont B, Somja J, et al. (2011) Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J Proteome Res 10: 4302-4313 doi:10.1021/pr200527z
47. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, et al. (2007) Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 121: 656-665 doi:10.1002/ijc.22558
48. Zhou W, Liang IC, Yee NS (2011) Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer. Cancer Biol Ther 11: 659-670 doi:10.4161/cbt. 11.7.14720
49. Iwahashi S, Shimada M, Utsunomiya T, Morine Y, Imura S, et al. (2011) Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-a on pancreatic cancer cells. Int J Clin Oncol 16: 671-678 doi:10.1007/s10147-011-0246-y
50. Jones J, Bertas W, Blaheta RA, Makarevic J, Hudak L, et al. (2008) Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid. Int J Mol Med 22: 293-299 doi: 10.3892/ijmm-00000022
51. Daniluk J, Liu Y, Deng D, Chu J, Huang H, et al. (2012) An NF-KB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 122: 1519-1528 doi:10.1172/JCI59743DS1
52. Takahashi H, Li A, Dawson DW, Hines OJ, Reber HA, et al. (2011) Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells. Pancreas 40: 453-459 doi:10.1097/MPA.0b013e31820b9733
53. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59: 4356-4362
54. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, et al. (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 40: 1347-1365 doi:10.1021/jm960803q
55. Padillo FJ, Ruiz-Rabelo JF, Cruz A, Perea MD, Tasset I, et al. (2010) Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. J Pineal Res 49: 264-270 doi:10.1111/j.1600-079X.2010.00791.x
56. Rosendahl AH, Gundewar C, Said K, Karnevi E, Andersson R (2012) Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition. Pancreatology 12: 219-226. doi: 10.1016/j.pan.2012.04.005
57. Zhang H, Chen P, Bai S, Huang C (2007) The histone deacetylase inhibitor MS-275 induces p21WAF1/Cip1 expression in human Hep3B hepatoma cells. Drug Dev Res 68: 61-70 doi:10.1002/ddr.20167
58. Ijichi H (2011) Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations. World J Clin Oncol 2: 195 doi: 10.5306/wjco. v2. i5.195
59. Lee MJ, Lee HS, Kim WH, Choi Y, Yang M (2003) Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol 16: 403-410 doi: 10.1097/01. MP.0000067683.84284.66
60. Allum WH, Stokes HJ, Macdonald F, Fielding JWL (1986) Demonstration of carcinoembryonic antigen (CEA) expression in normal, chronically inflamed, and malignant pancreatic tissue by immunohistochemistry. J Clin Pathol 39: 610-614. doi: 10.1136/jcp.39.6.610
61. Jeong S, Lee DH, Lee Jl, Lee JW, Kwon KS, et al. (2005) Expression of Ki-67, p53, and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma. World J Gastroenterol 11: 6765-6769
62. Naito Y, Kinoshita H, Okabe Y, Kawahara R, Sakai T, et al. (2006) CD56 (NCAM) expression in pancreatic carcinoma and the surrounding pancreatic tissue. Kurume Med J 53: 59-62. doi: 10.2739/kurumemedj.53.59
63. Reid MD, Bagci P, Adsay NV (2013) Histopathologic assessment of pancreatic cancer: Does one size fit all? J Surg Oncol 107: 67-77. doi: 10.1002/JSO.23194